首页> 外文期刊>European Radiology >Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief
【24h】

Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief

机译:Polidocanol硬化疗法治疗疼痛性静脉畸形:评估缓解疼痛的安全性和有效性

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to retrospectively evaluate the safety and efficacy of polidocanol sclerotherapy in pain relief for painful venous malformations (VMs). Thirty-one patients with painful VMs underwent polidocanol sclerotherapy. Pain intensity was assessed with an 11-point verbal numerical rating scale. Sclerotherapy was technically successful in 58 (98.3%) of 59 sessions. Twenty-six (89.7%) out of 29 patients experienced an improvement in pain after sclerotherapy at follow-up, a mean of 46 months after treatment. The mean pain score improved from 6.6 ± 2.5 before treatment to 2.4 ± 2.9 after treatment (P <.001). The factors that significantly influenced the therapeutic effect were size of lesion (P = .008), margin of lesion (P = .006), and stasis of sclerosant (P = .032). Adverse events included hypotension and bradycardia during the procedure. No major complication occurred. Polidocanol sclerotherapy is safe and most efficacious in providing pain relief for patients with small VMs (equal to or less than 10 cm in diameter), VMs with a well-defined margin, and VMs with good stasis of sclerosant during sclerotherapy.
机译:这项研究的目的是回顾性评估多多酚醇硬化疗法在缓解疼痛性静脉畸形(VMs)的疼痛中的安全性和有效性。 31例VM疼痛的患者接受了多巴酚醇硬化疗法。用11点口头数字评分量表评估疼痛强度。在59个疗程中,有58个(98.3%)的硬化疗法在技术上很成功。 29例患者中有26例(89.7%)在接受硬化治疗后平均随访46个月,疼痛得到改善。平均疼痛评分从治疗前的6.6±2.5改善到治疗后的2.4±2.9(P <.001)。显着影响治疗效果的因素是病变的大小(P = .008),病变的边缘(P = .006)和硬化剂的淤滞(P = .032)。不良反应包括低血压和心动过缓。没有大的并发症发生。聚多卡醇硬化疗法在小VM(直径等于或小于10厘米),边缘明确的VM和硬化过程中硬化剂停滞良好的VM的患者中提供疼痛缓解是最安全,最有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号